SERO Serologicals (MM)

Celliance Corporation, a wholly owned subsidiary of Serologicals Corporation (NASDAQ:SERO), announced today the execution of an expanded four-year supply agreement with Novo Nordisk A/S that provides Celliance the worldwide exclusive right to distribute Novo Nordisk's recombinant human insulin in the cell culture market. David A. Dodd, President and Chief Executive Officer of Serologicals Corporation, commented on the supply agreement, stating, "We are very pleased to have concluded this milestone agreement with Novo Nordisk. It represents years of hard work and successful collaboration on the part of both companies. Our relationship with Novo Nordisk began more than a decade ago when one of our predecessor companies began distributing Novo Nordisk's insulin into the cell culture market. Our colleagues at Novo Nordisk were quick to realize the importance of this market. They permitted us to develop it by affording us a dependable supply of the highest quality recombinant human insulin for our customers. The agreement that we just concluded allows us to renew our commitment to our cell culture customers for another four years. We will continue to market this important product to our customers under our Incelligent(TM) brand." Jesper Hoiland, Novo Nordisk's Senior Vice President of International Operations, said, "Novo Nordisk and Celliance have worked closely to build a leading position in the insulin segment of the global market for cell culture media. The new agreement creates a strong platform for increased growth and keeps leadership also in this segment." Celliance Corporation offers an expanding array of bioprocessing products and services including diagnostic products and cell culture media supplements. Key products include EX-CYTE(R), the largest selling cell growth supplement, Probumin(TM), a proprietary line of bovine serum albumin and Incelligent(TM), recombinant human insulin. It is also the world's leading provider of monoclonal antibodies for the blood typing industry. Celliance(TM) is a Serologicals company based in Atlanta, GA. Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA., is a global leader in developing and commercializing consumable biological products, enabling technologies and services. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, we are the world's leading provider of monoclonal antibodies for the blood typing industry. We employ a total of approximately 1,000 people worldwide in three companies: Chemicon International Inc., Upstate Group, LLC and Celliance Corporation. Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 22,000 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol `NVO'. For more information regarding Serologicals Corporation, please visit www.serologicals.com. For more information regarding Celliance Corporation, please visit www.celliancecorp.com. For more information regarding Novo Nordisk A/S, please visit www.novonordisk.com. Serologicals(R) and EX-CYTE(R) are registered trademarks of Serologicals Royalty Company. Incelligent(TM) and Probumin(TM) are trademarks of Serologicals Royalty Company.